Ecully, July 30, 2025 – 7 p.m. The Board of Directors of Spineway, meeting on July 30, 2025 under the chairmanship of Stéphane Le Roux, approved the financial statements for the six months to June 30, ...

LOS ANGELES, July 29, 2025 (GLOBE NEWSWIRE) -- UN Peace Ambassador Dr. Michael K. Obeng, the founder of Restore Worldwide, ...

Both the 20mg and 30mg onvansertib arms demonstrated an early separation of the PFS curves compared to the control arm at a ...

SupplyCopia's participation at AHRMM25 builds on the company's continued commitment to transforming healthcare supply chains through innovative AI solutions. The company's technology has helped health ...

Lecanemab received traditional approval in the U.S. in July 2023 for the treatment of early Alzheimer's disease (AD). This retrospective study was conducted to investigate the actual state of ...

Executive officers and members of Tevogen’s Board of Directors collectively hold over 74% of the Company’s outstanding shares. This substantial insider ownership reflects the leadership’s deep ...

The Canadian Red Cross extends its gratitude to Gary Slaight and The Slaight Family Foundation for a $1 million contribution over two years, in support of humanitarian efforts in Cox’s Bazar, ...

Title: Results from a Phase 1 expansion cohort of solnerstotug (pH-selective anti-VISTA antibody) combined with cemiplimab in patients with advanced solid tumors resistant to prior PD- (L)1 therapy ...

VLTR-559, a long-acting anti-VEGF therapy, could reduce dosing frequency for the treatment of wet AMD to twice-yearly, as compared to every eight to twelve weeks for standard-of-care anti-VEGFs ...

About BioNexus Gene Lab Corp. BGLC is an innovation-led life-sciences platform – bringing together precision diagnostics, cross-border expertise, and AI data development. Listed on Nasdaq, BGLC’s ...

Allen Institute to employ Iterative Mapping, Nautilus’ single-molecule proteomics method, to investigate connection between tau protein and Alzheimer’s disease • Agreement links the organizations’ ...

Preclinical data presented at SAWC, the largest wound care conference in the United States, highlighted the in vitro performance of revyve ®, including inhibition of key proteases such as matrix ...